Phase I study of ABBV|428

Phase I study of ABBV-428, a mesothelin-CD40 bispecific ... - PubMed

Conclusions: ABBV-428 monotherapy exhibited dose-proportional pharmacokinetics and an acceptable safety profile, particularly for toxicities characteristic of ...

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in ...

ABBV-428, a first-in-class, mesothelin-targeted, bispecific antibody designed for tumor microenvironment-dependent CD40 activation with limited systemic ...

CD40 bispecific, in patients (pts) with advanced solid tumours

Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific ...

Phase I study evaluating safety, pharmacokinetics (PK ...

Abstract. Background. ABBV-428 is a bispecific antibody designed for MSLN-dependent CD40 activation. Preliminary results of a phase I first-in ...

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation ...

Purpose. ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase ...

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO ...

Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (ELAHERE®), ...

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug ...

ABBV-085 is a monomethyl auristatin-E antibody–drug conjugate that targets LRRC15 and showed antineoplastic efficacy in preclinical experiments.

First-in-Human Phase I Study of ABBV-838, an Antibody ... - PubMed

ABBV-838 is an antibody-drug conjugate targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells.

Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics ...

ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups ...

A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ...

OX40 is a costimulatory molecule that is involved in enhancing nascent immune responses and concomitantly acts to suppress regulatory T-cell activity. ABBV-927 ...

(PDF) Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in ...

ABBV-428 represents a class of bispecific molecules with conditional activity dependent on the binding of a tumor-specific antigen, and such ...

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in ...

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. (16). Back to Profile. List ...

AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with ...

New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, ...

A Phase 1 Study of ABBV-400 in People With Advanced Solid Tumors

Full Title Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications Purpose Researchers want to ...

First-in-Human Phase I Study of ABBV-838, an Antibody–Drug ...

Despite the limited antitumor activity, ABBV-838 was seen to have a favorable safety profile. Thus, these data demonstrate that a ratio of two ...

An open-label, multicenter, phase I study of ABBV-399 ...

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small ...

ABBV-428 News - LARVOL Sigma

ABBV-428 / AbbVie. Clinical, P1 data, Journal, PD(L)-1 Biomarker, IO biomarker: Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with ...

Clinical Trials Using Anti-c-Met ADC ABBV-400 - NCI

Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help ...

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug ...

This phase 1 study evaluates safety and clinical activity of ABBV-319 monotherapy in patients with relapsed or refractory (R/R) B-cell malignancies.

ABBV-383 Myeloma Trials - SparkCures

View all active clinical trials around the US. A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies...